FDA declines to approve Regeneron's blood cancer therapy

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Aug 20, 2024 at 10:02: PM
via The U.S. Food and Drug Administration has declined to approve Regeneron's (REGN.O) therapy for a common form of blood cancer, the company said on Tuesday.

article source
 

<



Similar threads

cafead
FDA declines to approve Merck-Daiichi&#039;s &#039;guided missile&#039; cancer drug
Replies
0
Views
24
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA declines to approve Shin Nippon Biomedical&#039;s migraine drug
Replies
0
Views
57
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA declines to approve Astellas&#039; gastric cancer drug
Replies
0
Views
194
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
Immunitybio slumps as FDA declines to approve bladder cancer treatment
Replies
0
Views
107
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
FDA declines to approve Eli Lilly&#039;s bowel disease drug
Replies
0
Views
270
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote